JP2007277267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007277267A5 JP2007277267A5 JP2007195798A JP2007195798A JP2007277267A5 JP 2007277267 A5 JP2007277267 A5 JP 2007277267A5 JP 2007195798 A JP2007195798 A JP 2007195798A JP 2007195798 A JP2007195798 A JP 2007195798A JP 2007277267 A5 JP2007277267 A5 JP 2007277267A5
- Authority
- JP
- Japan
- Prior art keywords
- interacting
- drug combination
- fibrate
- combination according
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (7)
- (E)−7−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル](3R,5S)−3,5−ジヒドロキシヘプツ−6−エン酸又はその製剤的に許容される塩であるHMG−CoAレダクターゼ阻害剤と、フィブラート薬及び/又はナイアシンとを含んでなる、非相互作用性の医薬用薬物組み合わせ物。
- (E)−7−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル](3R,5S)−3,5−ジヒドロキシヘプツ−6−エン酸又はその製剤的に許容される塩と、フィブラート薬とを含んでなる、請求項1に記載の非相互作用性の医薬用薬物組み合わせ物。
- フィブラート薬がフィブル酸の構造/活性と類似している薬剤である、請求項2記載の非相互作用性の医薬用薬物組み合わせ物。
- フィブラート薬がフェノフィブラートである、請求項2記載の非相互作用性の医薬用薬物組み合わせ物。
- フィブラート薬がフェノフィブラートの遊離酸である、請求項2記載の非相互作用性の医薬用薬物組み合わせ物。
- (E)−7−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル](3R,5S)−3,5−ジヒドロキシヘプツ−6−エン酸又はその製剤的に許容される塩と、ナイアシンとを含んでなる、請求項1に記載の非相互作用性の医薬用薬物組み合わせ物。
- 高脂血症及び/又は高トリグリセリド血症を治療するための、請求項1〜6のいずれか1項に記載の非相互作用性薬物組み合わせ物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9902593.4A GB9902593D0 (en) | 1999-02-06 | 1999-02-06 | Drug combinations |
GBGB9921064.3A GB9921064D0 (en) | 1999-09-08 | 1999-09-08 | Drug combination |
GBGB9921063.5A GB9921063D0 (en) | 1999-09-08 | 1999-09-08 | Therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000596937A Division JP2002536331A (ja) | 1999-02-06 | 2000-02-01 | (e)−7−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル](3r,5s)−3,5−ジヒドロキシヘプツ−6−エン酸と、p450アイソザイム3a4の阻害剤、誘導剤又は基質を含んでなる薬物の組み合わせ |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007277267A JP2007277267A (ja) | 2007-10-25 |
JP2007277267A5 true JP2007277267A5 (ja) | 2008-05-15 |
Family
ID=27269637
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000596937A Pending JP2002536331A (ja) | 1999-02-06 | 2000-02-01 | (e)−7−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル](3r,5s)−3,5−ジヒドロキシヘプツ−6−エン酸と、p450アイソザイム3a4の阻害剤、誘導剤又は基質を含んでなる薬物の組み合わせ |
JP2007195798A Pending JP2007277267A (ja) | 1999-02-06 | 2007-07-27 | (e)−7−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル](3r,5s)−3,5−ジヒドロキシヘプツ−6−エン酸と、p450アイソザイム3a4の阻害剤、誘導剤又は基質を含んでなる薬物の組み合わせ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000596937A Pending JP2002536331A (ja) | 1999-02-06 | 2000-02-01 | (e)−7−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル](3r,5s)−3,5−ジヒドロキシヘプツ−6−エン酸と、p450アイソザイム3a4の阻害剤、誘導剤又は基質を含んでなる薬物の組み合わせ |
Country Status (29)
Country | Link |
---|---|
US (3) | US6982157B1 (ja) |
EP (1) | EP1185274B1 (ja) |
JP (2) | JP2002536331A (ja) |
KR (2) | KR20010101790A (ja) |
CN (1) | CN1165310C (ja) |
AR (1) | AR029333A1 (ja) |
AT (1) | ATE282415T1 (ja) |
AU (1) | AU767304B2 (ja) |
BR (1) | BR0007999A (ja) |
CA (1) | CA2358632C (ja) |
CZ (1) | CZ301296B6 (ja) |
DE (1) | DE60015965T2 (ja) |
EE (1) | EE04929B1 (ja) |
EG (1) | EG23858A (ja) |
ES (1) | ES2232418T3 (ja) |
GB (1) | GB0000710D0 (ja) |
HK (1) | HK1041817A1 (ja) |
ID (1) | ID30485A (ja) |
IL (1) | IL144715A0 (ja) |
IS (1) | IS2337B (ja) |
MX (1) | MXPA01007905A (ja) |
MY (1) | MY130606A (ja) |
NO (1) | NO320745B1 (ja) |
NZ (1) | NZ512982A (ja) |
PL (1) | PL198034B1 (ja) |
PT (1) | PT1185274E (ja) |
TR (1) | TR200102228T2 (ja) |
TW (1) | TWI282738B (ja) |
WO (1) | WO2000045817A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
CA2540984C (en) | 2003-10-10 | 2011-02-08 | Lifecycle Pharma A/S | A solid dosage form comprising a fibrate |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
JP2008509154A (ja) | 2004-08-06 | 2008-03-27 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なスタチン薬剤組成物および関連治療方法 |
WO2007005941A2 (en) | 2005-07-05 | 2007-01-11 | President And Fellows Of Harvard College | Liver targeted conjugates |
EA015682B1 (ru) * | 2005-12-20 | 2011-10-31 | Лек Фармасьютиклз Д.Д. | Фармацевтическая композиция |
US20080109252A1 (en) * | 2006-11-08 | 2008-05-08 | Lafountain Andrea | Predicting patient compliance with medical treatment |
US20120130202A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Musculoskeletal Pathologies |
CN112955965B (zh) * | 2018-06-14 | 2024-04-09 | 阿斯利康(英国)有限公司 | 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法 |
JP2022542004A (ja) | 2019-07-31 | 2022-09-29 | インタス ファーマシューティカルズ リミテッド | HMG-CoAレダクターゼ阻害剤及びフェノフィブラートを含む医薬組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
ATE114286T1 (de) * | 1991-07-02 | 1994-12-15 | Benckiser Gmbh Joh A | Zusammenfaltbare vorratsflasche. |
JP3852621B2 (ja) * | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | 血管内皮細胞機能改善剤 |
FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
EP1027045A4 (en) * | 1997-10-31 | 2004-12-08 | Arch Dev Corp | METHODS AND COMPOSITIONS FOR REGULATING 5-ALPHA-REDUCTASE ACTIVITY |
-
2000
- 2000-01-14 GB GBGB0000710.4A patent/GB0000710D0/en not_active Ceased
- 2000-02-01 NZ NZ512982A patent/NZ512982A/en not_active IP Right Cessation
- 2000-02-01 JP JP2000596937A patent/JP2002536331A/ja active Pending
- 2000-02-01 EP EP00901264A patent/EP1185274B1/en not_active Expired - Lifetime
- 2000-02-01 CN CNB008034702A patent/CN1165310C/zh not_active Expired - Lifetime
- 2000-02-01 AT AT00901264T patent/ATE282415T1/de active
- 2000-02-01 IL IL14471500A patent/IL144715A0/xx not_active IP Right Cessation
- 2000-02-01 AU AU21218/00A patent/AU767304B2/en not_active Expired
- 2000-02-01 ID IDW00200101892A patent/ID30485A/id unknown
- 2000-02-01 KR KR1020017009914A patent/KR20010101790A/ko active Search and Examination
- 2000-02-01 MX MXPA01007905A patent/MXPA01007905A/es not_active IP Right Cessation
- 2000-02-01 WO PCT/GB2000/000278 patent/WO2000045817A1/en not_active Application Discontinuation
- 2000-02-01 CZ CZ20012844A patent/CZ301296B6/cs not_active IP Right Cessation
- 2000-02-01 TR TR2001/02228T patent/TR200102228T2/xx unknown
- 2000-02-01 EE EEP200100406A patent/EE04929B1/xx unknown
- 2000-02-01 US US09/889,414 patent/US6982157B1/en not_active Expired - Lifetime
- 2000-02-01 CA CA002358632A patent/CA2358632C/en not_active Expired - Fee Related
- 2000-02-01 BR BR0007999-5A patent/BR0007999A/pt not_active Application Discontinuation
- 2000-02-01 PL PL364780A patent/PL198034B1/pl unknown
- 2000-02-01 PT PT00901264T patent/PT1185274E/pt unknown
- 2000-02-01 DE DE60015965T patent/DE60015965T2/de not_active Expired - Lifetime
- 2000-02-01 KR KR1020067021986A patent/KR20060117381A/ko not_active Application Discontinuation
- 2000-02-01 ES ES00901264T patent/ES2232418T3/es not_active Expired - Lifetime
- 2000-02-04 AR ARP000100507A patent/AR029333A1/es unknown
- 2000-02-04 MY MYPI20000416A patent/MY130606A/en unknown
- 2000-02-22 EG EG20000124A patent/EG23858A/xx active
- 2000-05-11 TW TW089102105A patent/TWI282738B/zh not_active IP Right Cessation
-
2001
- 2001-07-17 IS IS6009A patent/IS2337B/is unknown
- 2001-08-03 NO NO20013811A patent/NO320745B1/no not_active IP Right Cessation
-
2002
- 2002-05-08 HK HK02103512A patent/HK1041817A1/xx unknown
-
2005
- 2005-03-15 US US11/079,530 patent/US20060040969A1/en not_active Abandoned
-
2007
- 2007-07-27 JP JP2007195798A patent/JP2007277267A/ja active Pending
-
2008
- 2008-09-29 US US12/285,117 patent/US20090042911A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007277267A5 (ja) | ||
HRP20161577T1 (hr) | Inhibitori replikacije virusa gripe | |
JP2013543896A5 (ja) | ||
EA200901442A1 (ru) | Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах | |
JP2017504611A5 (ja) | ||
IS8478A (is) | Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess | |
CR6687A (es) | Composiciones farmaceuticas que comprenden inhibidoras de la hmg coa reductasa | |
CY1117978T1 (el) | Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a | |
LTC1562603I2 (lt) | Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui | |
JP2008526861A5 (ja) | ||
IS2689B (is) | Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts | |
JP2011524850A5 (ja) | ||
JP2016521279A5 (ja) | ||
JP2014511891A5 (ja) | ||
JP2006508953A5 (ja) | ||
NZ594369A (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
WO2009157014A3 (en) | A process for preparing hmg-coa reductase inhibitors and intermediates | |
EA200801447A1 (ru) | Фармацевтическая композиция | |
BRPI0406455A (pt) | Combinação farmacêutica para profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais | |
RS54293B1 (en) | PHARMACEUTICAL COMBINATION | |
WO2008020314A3 (en) | Statin stabilizing dosage formulations | |
PL1704144T3 (pl) | Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego | |
WO2010030201A3 (en) | Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid | |
JP2015509917A5 (ja) | ||
CY1111430T1 (el) | Χρηση της αγομελατινης για τη ληψη φαρμακων που προοριζονται για τη θεραπεια του συνδρομου smith magenis |